Analytical challenges in the detection of peptide hormones for anti-doping purposes

Bioanalysis

Volumn 4, Issue 13, 2012, Pages 1577-1590

  Barroso, Osquel ^a   Handelsman, David J ^b   Strasburger, Christian ^c   Thevis, Mario ^d  

^a World Anti Doping Agency (WADA)   (Canada)

^b ANZAC RESEARCH INSTITUTE   (Australia)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CHORIONIC GONADOTROPIN; DESMOPRESSIN; ERYTHROPOIETIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; HUMAN GROWTH HORMONE; INSULIN DERIVATIVE; LUTEINIZING HORMONE; PEGINESATIDE; PEPTIDE HORMONE; RECOMBINANT CHORIONIC GONADOTROPIN; SOMATOMEDIN C; TESTOSTERONE;

ANEMIA; ATHLETIC PERFORMANCE; BLOOD SAMPLING; DOPING; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG STRUCTURE; HORMONE DETERMINATION; IMMUNOASSAY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROSTATE CANCER; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; URINALYSIS;

ANABOLIC AGENTS; ATHLETES; BIOLOGICAL MARKERS; DOCUMENTATION; DOPING IN SPORTS; HEMATINICS; HUMAN GROWTH HORMONE; HUMANS; INTERNATIONAL AGENCIES; MASS SPECTROMETRY; METABOLOMICS; PEPTIDE HORMONES; PERFORMANCE-ENHANCING SUBSTANCES; PROTEOMICS; SUBSTANCE ABUSE DETECTION;

EID: 84864438319     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.128     Document Type: Review

References (107)

1. Barroso O, Mazzoni I, Rabin O. Hormone abuse in sports: The anti-doping perspective. Asian J. Androl. 10(3), 391-402 (2008).
2. Baumann G. Growth hormone isoforms. Growth Horm. IGF Res. 19(4), 333-340 (2009).
3. Alfthan H, Haglund C, Dabek J, Stenman UH. Concentrations of human chorionic gonadotrophin, its b-subunit and the core fragment of the b-subunit in serum and urine of men and non-pregnant women. Clin. Chem. 38(10), 1981-1987 (1992).
4. Bristow A, Berger P, Bidart JM et al. Establishment, value assignment, and characterization of new WHO reference reagents for six molecular forms of human chorionic gonadotropin. Clin. Chem. 51(1), 177-182 (2005).
5. Fredolini C, Tamburro D, Gambara G et al. Nanoparticle technology: Amplifying the effective sensitivity of biomarker detection to create a urine test for hGH. Drug Test. Anal. 1(9-10), 447-454(2009).
6. Lasne F, Martin L, Crepin N, De Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: Differentiation of natural and administered recombinant hormones. Anal. Biochem. 311(2), 119-126 (2002).
7. Lamon S, Giraud S, Egli L et al. A high-throughput test to detect C.E.R.A. doping in blood. J. Pharm. Biomed. Anal. 50(5), 954-958 (2009).
8. Thomas M, Kohler M, Schänzer W, Delahaut P, Thevis M. Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. Analyst 136(5), 1003-1012 (2011).
9. Thevis M, Thomas A, Schänzer W. Doping control analysis of selected peptide hormones using LC-MS(/MS). Forensic Sci. Int. 213(1-3), 35-41 (2011).
10. Bredehöft M, Schänzer W, Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography-electrospray ionisation tandem mass spectrometry. Rapid Commun. Mass Spectrom. 22(4), 477-485 (2008).
11. Erotokritou-Mulligan I, Guha N, Stow M et al. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Growth Horm. IGF Res. 22(2), 53-58 (2012).
12. Sottas PE, Robinson N, Saugy M. The athlete's biological passport and indirect markers of blood doping. Handb Exp. Pharmacol. 195, 305-326 (2010).
13. Stübiger G, Marchetti M, Nagano M et al. Characterization of N- and O-glycopeptides of recombinant human erythropoietins as potential biomarkers for doping analysis by means of microscale sample purification combined with MALDI-TOF and quadrupole IT/RTOF mass spectrometry. J. Sep. Sci. 28(14), 1764-1778 (2005).
14. Yu NH, Ho EN, Wan TS, Wong AS. Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography- tandem mass spectrometry. Anal. Bioanal. Chem. 396(7), 2513-2521 (2010).
15. Girard M, Puerta A, Diez-Masa JC, De Frutos M. High resolution separation methods for the determination of intact human erythropoiesis stimulating agents. A review. Anal. Chim. Acta 713, 7-22 (2012).
16. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W. Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal. Chem. 77 (11), 3579-3585 (2005).
17. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W. Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry. Anal. Chem. 78(6), 1897-1903 (2006).
18. Thomas A, Thevis M, Delahaut P, Bosseloir A, Schänzer W. Mass spectrometric identification of degradation products of insulin and its long-acting analogues in human urine for doping control purposes. Anal. Chem. 79(6), 2518-2524 (2007).
19. Thevis M, Thomas A, Schänzer W. Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom. Rev. 27(1), 35-50 (2008).
20. Thomas A, Schänzer W, Delahaut P, Thevis M. Sensitive and fast identification of urinary human, synthetic and animal insulin by means of nano-UPLC coupled with high resolution/ high accuracy mass spectrometry. Drug Test. Anal. 1(5), 219-227 (2009).
21. Thevis M, Bredehöft M, Kohler M, Schänzer W. Mass spectrometry-based analysis of IGF-1 and hGH. Handb Exp. Pharmacol. 195, 201-207 (2010).
22. Arsene CG, Henrion A, Diekmann N, Manolopoulou J, Bidlingmaier M. Quantification of growth hormone by isotope dilution mass spectrometry. Anal. Biochem. 401(2), 228-235 (2010).
23. Liu C, Bowers LD. Mass spectrometric characterization of nicked fragments of the beta-subunit of human chorionic gonadotropin. Clin. Chem. 43(7), 1172-1181 (1997).
24. Black RS, Bowers LD. Mass spectrometric characterization of the beta-subunit of human chorionic gonadotropin. Methods Mol. Biol. 146, 337-354 (2000).
25. Ramirez-Llanelis R, Llop E, Ventura R, Segura J, Gutierrez-Gallego R. Can glycans unveil the origin of glycoprotein hormones? Human chorionic gonadotrophin as an example. J. Mass Spectrom. 43(7), 936-948 (2008).
26. Kicman AT, Parkin MC, Iles RK. An introduction to mass spectrometry based proteomics-detection and characterization of gonadotropins and related molecules. Mol. Cell Endocrinol. 260-262, 212-227 (2007).
27. Thevis M, Schänzer W. Mass spectrometric identification of peptide hormones in doping control analysis. Analyst. 132(4), 287-292 (2007).
28. Thevis M, Bredehöft M, Geyer H, Kamber M, Delahaut P, Schänzer W. Determination of Synacthen in human plasma using immunoaffinity purification and liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20(23), 3551-3556 (2006).
29. Thomas A, Kohler M, Schanzer W, Kamber M, Delahaut P, Thevis M. Determination of Synacthen in urine for sports drug testing by means of nano-ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 23(17), 2669-2674 (2009).
30. Chaabo A, De Ceaurriz J, Buisson C, Tabet JC, Lasne F. Simultaneous quantification and qualification of synacthen in plasma. Anal. Bioanal. Chem. 399(5), 1835-1843 (2011).
31. Thomas A, Geyer H, Kamber M, Schänzer W, Thevis M. Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS. J. Mass Spectrom. 43(7), 908-915 (2008).
32. Thomas A, Guddat S, Kohler M et al. Comprehensive plasma-screening for known and unknown substances in doping controls. Rapid Commun. Mass Spectrom. 24(8), 1124 (2010).
33. Thomas A, Hoppner S, Geyer H et al. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 401, 507-516 (2011).
34. Möller I, Thomas A, Geyer H, Schänzer W, Thevis M. Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. Rapid Commun. Mass Spectrom. 25(15), 2115-2123 (2011).
35. Bidlingmaier M, Suhr J, Ernst A et al. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin. Chem. 55(3), 445-453 (2009).
36. Wood P. Growth hormone: Its measurement and the need for assay harmonization. Ann. Clin. Biochem. 38(Pt 5), 471-482 (2001).
37. Clemons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin. Chem. 57(4), 4555-4559 (2011).
38. Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E. How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy. J. Clin. Endocrinol. Metab. 83(4), 1211-1216 (1998).
39. Chestnut RE, Quarmby V. Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients. J. Immunol. Method. 259(1-2), 11-24 (2002).
40. Ranke MB, Osterziel KJ, Schweizer R et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: Comparison of four immunoassays. Clin. Chem. Lab. Med. 41(10), 1329-1334 (2003).
41. Khosravi J, Diamandi A, Bodani U, Khaja N, Krishna RG. Pitfalls of immunoassay and sample for IGF-I: Comparison of different assay methodologies using various fresh and stored serum samples. Clin. Biochem. 38(7), 659-666 (2005).
42. Krebs A, Wallaschofski H, Spilcke-Liss E et al. Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population. Clin. Chem. Lab. Med. 46(12), 1776-1783 (2008).
43. Sturgeon CM, Berger P, Bidart JM et al. IFCC Working Group on hCG. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin. Chem. 55(8), 1484-1491 (2009).
44. Cole LA, DuToit S, Higgins TN. Total hCG tests. Clin. Chim. Acta 412(23-24), 2216-2222 (2011).
45. Gold L, Ayers D, Bertino J et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5(12), e15004 (2010).
46. Segura J, Pascual JA, Guitérrez-Gallego R. Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal. Bioanal. Chem. 388(7), 1521-1529 (2007).
47. Reichel C. Recent developments in doping testing for erythropoietin. Anal. Bioanal. Chem. 401(2), 463-481 (2011).
48. Leuenberger N, Reichel C, Lasne F. Detection of erythropoiesis- stimulating agents in human anti-doping control: Past, present and future. Bioanalysis 4(13) 1565-1575 (2012).
49. Leuenberger N, Saugy J, Mortensen RB, Schatz PJ, Giraud S, Saugy M. Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples. Forensic Sci. Int. 213(1-3), 15-19 (2011).
50. Wrighton NC, Balasubramanian P, Barbone FP et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat. Biotechnol. 15(12), 1261-1265 (1997).
51. Macdougall IC, Rossert J, Casadevall N et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N. Engl. J. Med. 361(19), 1848-1855 (2009).
52. Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J. Clin. Pharmacol. 48(1), 43-52 (2008).
53. Del Vecchio L, Cavalli A, Tucci B, Locatelli F. Chronic kidney disease-associated anemia: New remedies. Curr. Opin. Investig. Drugs 11(9), 1030-1038 (2010).
54. Handelsman DJ. Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport. J. Clin. Endocrinol. Metab. 91(5), 1646-1653 (2006).
55. Valmu L, Alfthan H, Hotakainen K, Birken S, Stenman UH. Site-specific glycan analysis of human chorionic gonadotropin beta-subunit from malignancies and pregnancy by liquid chromatography-electrospray mass spectrometry. Glycobiology 16(12), 1207-1218 (2006).
56. Liu PY, Baker HW, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ. Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: Predictors of fertility outcome. J. Clin. Endocrinol. Metab. 94(3), 801-808 (2009).
57. Veldhuis JD, Iranmanesh A. Pulsatile intravenous infusion of recombinant human luteinizing hormone under acute gonadotropin-releasing hormone receptor blockade reconstitutes testosterone secretion in young men. J. Clin. Endocrinol. Metab. 89(9), 4474-4479 (2004).
58. Handelsman DJ, Goebel C, Idan A, Jimenez M, Trout G, Kazlauskas R. Effects of recombinant human LH and hCG on serum and urine LH and androgens in men. Clin. Endocrinol. (Oxf.) 71(3), 417-428 (2009).
59. Cole LA. Familial hCG syndrome. J. Reprod. Immunol. 93(1), 52-57 (2012).
60. Bristow A, Berger P, Bidart JM et al. Establishment, value assignment, and characterization of new WHO reference reagents for six molecular forms of human chorionic gonadotropin. Clin. Chem. 51(1), 177-182 (2005).
61. Stenman UH, Unkila-Kallio L, Korhonen J, Alfthan H. Immunoprocedures for detecting human chorionic gonadotropin: Clinical aspects and doping control. Clin Chem. 43(7), 1293-1298 (1997).
62. Stenman UH, Hotakainen K, Alfthan H. Gonadotropins in doping: Pharmacological basis and detection of illicit use. Br. J. Pharmacol. 154(3), 569-583 (2008).
63. Lempiäinen A, Hotakainen K, Alfthan H, Stenman UH. Loss of human chorionic gonadotropin in urine during storage at -20°C. Clin. Chim. Acta 413(1-2), 232-236 (2012).
64. Varki A. Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. Am. J. Phys. Anthropol. Suppl. 33, 54-69 (2001).
65. Gervais A, Hammel YA, Pelloux S et al. Glycosylation of human recombinant gonadotrophins: Characterization and batch-to-batch consistency. Glycobiology 13(3), 179-189 (2003).
66. Handelsman DJ, Swerdloff RS. Pharmacokinetics of gonadotropin-releasing hormone and its analogs. Endocr. Rev. 7(1), 95-105 (1986).
67. Tay CC. Use of gonadotrophin-releasing hormone agonists to trigger ovulation. Hum. Fertil. (Camb.) 5(1), G35-G37; discussion G38-G39, G41-G38 (2002).
68. Tsushima T, Nasu Y, Saika T et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol. Int. 66(3), 135-139 (2001).
69. Toro I, Sanz-Nebot V, Barbosa J. Analysis of a peptide hormone mixture of therapeutic interest by liquid chromatography coupled to high-flow pneumatically assisted electrospray mass spectrometry. J. Chromatogr. A 893(1), 95-106 (2000).
70. Zhan Y, Chen X, Zhao X, Zhong D. Rapid and sensitive liquid chromatography-tandem mass spectrometry method for the determination of leuprolide in human serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(27), 3194-3200 (2009).
71. Raiman J, Koljonen M, Huikko K, Kostiainen R, Hirvonen J. Delivery and stability of LHRH and Nafarelin in human skin: The effect of constant/pulsed iontophoresis. Eur. J. Pharm. Sci. 21(2-3), 371-377 (2004).
72. Barroso O, Schamasch P, Rabin O. Detection of GH abuse in sport: Past, present and future. Growth. Horm. IGF Res. 19(4), 369-374 (2009).
73. Baumann GP. Growth Hormone Doping in Sports: A critical review of use and detection strategies. Endocr. Rev. 33(2), 155-186 (2012).
74. Miles LE, Hales CN. Labelled antibodies and immunological assay systems. Nature 219(5150), 186-189 (1968).
75. Seth J, Ellis A, Al-Sadie R. Serum growth hormone measurements in clinical practice: An audit of performance from the UK National External Quality Assessment scheme. Horm. Res. 51(Suppl. 1), 13-19 (1999).
76. Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson-Wikland K. Growth hormone (GH) assays: Influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin. Chem. 43(6 Pt 1), 950-956 (1997).
77. Baumann G, Stolar MW, Amburn K. Molecular forms of circulating growth hormone during spontaneous secretory episodes and in the basal state. J. Clin. Endocrinol. Metab. 60(6), 1216-1220 (1985).
78. Pagani S, Cappa M, Meazza C et al. Growth hormone isoforms release in response to physiological and pharmacological stimuli. J. Endocrinol. Invest. 31, 520-524 (2008).
79. Wu Z, Bidlingmaier M, Rolf D, Strasburger CJ. Detection of doping with human growth hormone. The Lancet 353, 895 (1999).
80. Bidlingmaier M, Wu Z, Strasburger CJ. Test method: gh. Bailliere's Clin. Endocrinol. Metab. 14(1), 99-109 (2000).
81. Powrie JK, Bassett EE, Rosen T et al. Detection of growth hormone abuse in sport. Growth. Horm. IGF Res. 17, 220-226 (2007).
82. Erotokritou-Mulligan I, Bassett EE, Kniess A, Sönksen PH, Holt RIG. Validation of the growth hormone (GH)-dependent marker method of detecting GH abuse in sport through the use of independent data sets. Growth. Horm. IGF Res. 17(5), 416-423 (2007).
83. Wallace JD, Cuneo RC, Baxter R et al. Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: A potential test for GH abuse in sport. J. Clin. Endocrinol. Metab. 84(10), 3591-3601 (1999).
84. Longobardi S, Keay N, Ehrnborg C et al. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: A double blind, placebo-controlled study. The GH-2000 study group. J. Clin. Endocrinol. Metab. 85(4), 1505-1512 (2000).
85. Wallace JD, Cuneo RC, Lundberg PA et al. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J. Clin. Endocrinol. Metab. 85(1), 124-133 (2000).
86. Jones JI, Clemmons DR. Insulin-like growth factors, and their binding proteins. Endocr, Rev. 16, 3-34 (1995).
87. Horner JM, Liu F, Hintz RL. Comparison of 125I-somatomedin A and 125I-somatomedin C in radioreceptor assays for somatomedin peptide content in whole and acid-chromatographed plasma. J. Clin. Endocr. Metab. 47, 1287-1295 (1978).
88. Blum WF, Ranke MB, Bierich JR. A specific radioimmunoassay for insulin-like growth factor II: The interference of IGF binding proteins can be blocked by excess IGF-I. Acta Endocrinol. (Copenh). 118(3), 374-380 (1988).
89. Holt RI, Erotokritou-Mulligan I, Ridley SA et al. A determination of the pre-analytical storage conditions for insulin like growth factor-I and type III procollagen peptide. Growth. Horm. IGF Res. 19(1), 43-50 (2009).
90. Hepner F, Csaszar E, Roitinger E, Pollak A, Lubec G. Mass spectrometrical analysis of recombinant human growth hormone Norditropin reveals amino acid exchange at M14-V14rhGH. Proteomics 6(3), 775-784 (2006).
91. Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA. Quantitative mass spectrometric immunoassay of insulin like growth factor 1. J. Proteome Res. 3(4), 851-855 (2004).
92. Kirsch S, Widart J, Louette J, Focant JF, De Pauw E. Development of an absolute quantification method targeting growth hormone biomarkers using liquid chromatography coupled to isotope dilution mass spectrometry. J. Chromatogr. A 1153(1-2), 300-306 (2007).
93. Barton C, Kay RG, Gentzer W, Vitzthum F, Pleasance S. Development of high-throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) assays for clinically relevant plasma proteins. J. Proteome Res. 9(1), 333-340 (2010).
94. Kay RG, Barton C, Velloso CP et al. High-throughput ultra-high- performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich a-2- glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun. Mass Spectrom. 23(19), 3173-3182 (2009).
95. Popot MA, Woolfitt AR, Garcia P, Tabet JC. Determination of IGF-I in horse plasma by LC electrospray ionisation mass spectrometry. Anal. Bioanal. Chem. 390(7), 1843-1852 (2008).
96. Okano M, Nishitani Y, Sato M, Ikekita A, Kageyama S. Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: Growth hormone isoform profiles in Japanese male subjects. Drug Test. Anal. 2(11-12), 548-556 (2010).
97. Bowers CY, Laferrère B, Hurley DL, Veldhuis JD. The role of growth hormone secretagogues and ghrelin in feeding and body composition. In: ENERGY Metabolism and Obesity. Donohoue PA (Ed.). Humana Press, NJ, USA, 125 (2008).
98. Thomas A, Kohler M, Mester J et al. Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. Drug Test. Anal. 2(3), 144-148 (2010).
99. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test. Anal. 2(11-12), 647-650 (2010).
100. Sanchis-Gomar F, Martinez-Bello VE, Nascimento AL et al. Desmopresssin and hemodilution: Implications in doping. Int. J. Sports Med. 31(1), 5-9 (2010).
101. Thomas A, Solymos E, Schänzer W et al. Determination of Vasopressin and Desmopressin in urine by means of liquid chromatography coupled to quadrupole time-of-flight mass spectrometry for doping control purposes. Anal. Chim. Acta 707(1-2), 107-113 (2011).
102. Reichel C. OMICS-strategies and methods in the fight against doping. Forensic Sci. Int. 213, 20-34 (2011).
103. Van Renterghem P, Van Eenoo P, Sottas PE, Saugy M, Delbeke F. Subject-based steroid profiling and the determination of novel biomarkers for DHT and DHEA misuse in sports. Drug Test. Anal. 2(11-12), 582-588 (2010).
104. Chung L, Baxter RC. Detection of growth hormone responsive proteins using SELDI-TOF mass spectrometry. Growth Horm. IGF Res. 19(4), 383-387 (2009).
105. Brun V, Masselon C, Garin J, Dupuis A. Isotope dilution strategies for absolute quantitative proteomics. J. Proteom. 72, 740-749 (2009).
106. Ciccimaro E, Blair IA. Stable-isotope dilution LC-MS for quantitative biomarker analysis. Bioanalysis 2(2), 311-341 (2010).
107. Bruno JG, Carrillo MP, Phillips T, Edge A. Discrimination of recombinant from natural human growth hormone using DNA aptamers. J. Biomol. Tech. 22(1), 27-36 (2011).